Treatment toxicity
thrombocytopenia, leucopenia/neutropenia
ADVERSE EVENTS, THROMBOCYTOPENIA
No adverse events concerning HIPEC treatment were observed in the HIPEC group. Grade 3 or 4 adverse events concerning postoperative chemotherapy were found in 19 patients, including 11 (16.4%) patients in the HIPEC group and 8 (11.9%) patients in the non-HIPEC group, and there was no significant difference between the two groups. Among the whole study cohort, leucopenia/neutropenia (7 patients, 5.2%) and thrombocytopenia (6 patients, 4.5%) were the most common hematological toxic effects, while elevated serum AST levels (11 patients, 8.2%) were the most common nonhematological toxic effect (Table Grade 3 or 4 toxic effects in the HIPEC group and the non-HPIEC group